Introduction
The goal of most current cancer therapies, including radiation, chemotherapy, immunotherapy, and gene therapy, is the reduction or elimination of cancer cells. Although cytostatic effects, if complete and durable, might be acceptable in some settings, the current regulatory climate favors the development of cytotoxic agents. Despite the approval of B100 such agents for the treatment of cancer, however, the age-adjusted death rate from most common epithelial neoplasms has scarcely changed in the past four decades (Greenlee et al., 2001 ). These observations suggest that cytotoxic agents often fail to selectively eradicate neoplastic cells and provide the impetus for asking whether there is something wrong with the cell death process in cancer cells.
All cells are mortal
As a starting point, it is important to emphasize that all cells, whether normal or neoplastic, can be killed. If a drug or toxin blocks a metabolic process that is essential for cell survival, the cell will die. Given at high enough doses, any agent that inhibits an important process, such as protein synthesis, ATP production, or the ability to maintain plasma membrane integrity, will be able to kill all cancer cells. The obvious problem is that such a treatment would probably kill all normal cells as well, leading to death of the patient.
Most cells can be suicidal
A second point to emphasize at the outset is that chemotherapeutic agents can have two distinct but related effects on cells. As outlined in Figure 1 , they can directly block a vital cellular process, and they can stress a cell, indirectly prompting it to kill itself. Either or both of these effects can contribute to cell death.
The first effect can be adequately described by a 'lock and key' model. For example, paclitaxel alters b-tubulin function, methotrexate blocks dihydrofolate reductase, and camptothecin inhibits the religation step of DNA topoisomerase I. For these types of agents, the drug-target interaction has been shown to cause cellular changes that could result in cell death. Paclitaxel, for example, causes mitotic arrest followed by exit into an aberrant G 1 -like tetraploid state characterized by markedly abnormal nuclear : cytoplasmic communica-tion (Theodoropoulos et al., 1999; Blajeski and Kaufmann, 2001) . Camptothecin-induced trapping of covalent topoisomerase I-DNA complexes, on the other hand, leads to DNA double-strand breaks and mutations that, if they occur in survival-critical genes, could result in death once the corresponding polypeptides turn over (Ryan et al., 1991; Hashimoto et al., 1995) .
The second effect of chemotherapeutic agents results in a response in which cells kill themselves by activating an endogenous cell suicide process (Kaufmann and Earnshaw, 2000) . This form of cell death, often recognizable by its characteristic appearance known as 'apoptosis,' uses effector mechanisms that are also employed for the removal of unwanted cells during development and to maintain constant cell number by balancing mitosis (Arends and Wyllie, 1991) . Stress responses, including cell suicide, are much more complicated than the 'lock and key' processes described above. These are more appropriately thought of as a 'stimulus-response model' in which a cell needs receptors to sense an alteration, signal transduction pathways to pass on the information, and effector mechanisms to mediate a response. For example, exposure of a cell to ionizing radiation leads to detection of DNA lesions, activation of a series of kinases, and recruitment and/or synthesis of a series of polypeptides that can block the cell cycle and repair the damage or cause the cell to kill itself (Zhou and Elledge, 2000; Abraham, 2001) .
The recognition that chemotherapeutic agents can kill cancer cells in these two fundamentally different ways raises a number of important questions: Which mechanism, direct killing or induction of apoptosis, is more important therapeutically? Do alterations of apoptotic pathway components contribute to resistance? Would novel therapies that enhance the apoptotic mechanism be clinically useful, either alone or in combination with conventional chemotherapeutic agents? In order to address these questions, it is first important to understand the nature of the apoptotic machinery and its regulation.
Apoptosis mechanisms
Studies in the nematode Caenorhabditis elegans, the fly Drosophila melanogaster, and mammalian cells have demonstrated that the biochemical mechanisms leading to apoptosis are highly conserved among metazoans. These mechanisms have been extensively reviewed (Adams and Cory, 1998; Metzstein et al., 1998; Hengartner, 2000; Zimmermann et al., 2001; Martin, 2002) and are only briefly summarized here.
In all of these organisms, the key effector proteins of apoptosis are a family of cysteine proteases termed caspases that, once activated, cleave their substrates after certain aspartic acid residues (Earnshaw et al., 1999; Nicholson, 1999) . Over 200 caspase substrates, some of which are required for the cell to maintain viability, have been identified in mammalian cells. For example, when inhibitor of caspase-activated DNase (ICAD) is cleaved by caspases, it releases the constitutively expressed endonuclease caspase-activated DNase (CAD), which then cleaves the nuclear DNA (Liu et al., 1997; Enari et al., 1998) . Although DNA degradation is incompatible with long-term cell survival, and has provided a convenient marker allowing detection of apoptotic mammalian cells, it is important to emphasize that proteolysis, rather than DNA degradation, is the key regulatory event in apoptosis. In addition to nuclease activation, proteolysis results in diminished DNA repair, disruption of cell-cycle progression, inhibition of protein synthesis, cleavage of major structural proteins in the cytoplasm and nucleus, and disruption of signal transduction required for cellular homeostasis (Earnshaw et al., 1999) .
The caspases responsible for this proteolysis are synthesized as inactive precursors (zymogens) that must be activated either by cleavage or conformational change before they can cleave their substrates (Earnshaw et al., 1999; Nicholson, 1999) . Caspase 3, a socalled 'downstream' or 'effector' caspase that is responsible for most of the cleavages that occur during apoptosis (Slee et al., 2001; Kottke et al., 2002) , is activated when it is cleaved by 'upstream' or 'initiator' caspases such as caspases 8, 9, or 10. In addition to . Figure 1 Two types of responses to anticancer therapy. Most toxins, radiation, and chemotherapeutic agents can directly damage both normal and cancer cells. If the damage is severe enough and sustained for a sufficient time, it will kill a cell directly as illustrated by examples in the text. If the damage is not as great, or it has not had enough time to kill the cell directly, the cell might detect the damage and respond. Some responses allow the cell to repair the damage, thereby helping protect the cell. Apoptosis is a common stress response in which the cell kills itself. Because of differences in some of the properties described in other reviews in this monograph (e.g. drug uptake, xenobiotic metabolism, and target abundance), normal cells and cancer cells might have different thresholds for direct toxicity. Likewise, because of differences in signals that regulate apoptotic pathways, normal cell and cancer cells can have differences in apoptotic thresholds cleaving vital protein substrates within the cell, effector caspases can cleave and activate initiator caspases in an amplification loop (Slee et al., 1999) .
Mechanisms of caspase activation are remarkably conserved from C. elegans to Drosophila to man (see Figure 2 and Table 1 ). In each case, the initiator caspases are activated by adaptor proteins. For example, in mammalian cells, the adaptor Fas-associated polypeptide with death domain (FADD) can bind to and activate caspases 8 and 10, and the adaptor Apoptotic protease activating factor-1 (Apaf-1) can bind to and activate caspase 9. These procaspaseadaptor protein interactions involve specialized protein interaction domains called death effector domains and caspase recruitment domains in the prodomains of the initiator caspases (Earnshaw et al., 1999; Nicholson, 1999; Hengartner, 2000) . In the case of caspase 9, it is now clear that the activating event is an Apaf-1-induced dimerization that drives a conformational change at the active site of the zymogen (Renatus et al., 2001) . Signalinduced activation of other initiator caspases presumably involves similar changes (Boatright, 2003) .
Many different signal transduction pathways can lead to activation of the initiator caspases. For convenience, these are often grouped together (Budihardjo et al., 1999; Hengartner, 2000) . Ligation of certain tumor necrosis factor-a (TNF) receptor family members, for example, TNFR1, Fas, or death receptors 4 and 5, often leads to apoptosis involving FADD and caspases 8 and 10 as a consequence of signaling through what is termed the 'extrinsic pathway' or the 'death receptor pathway' (Ashkenazi, 2002) . Apoptosis induced in this way is rarely inhibitable by overexpression of antiapoptotic Bcl-2 family members (see below) (Strasser et al., 1995; Newton and Strasser, 2000) . On the other hand, apoptosis induced by radiation, p53, glucocorticoids, cytokine deprivation, and most chemotherapeutic drugs usually leads to apoptosis that involves Apaf-1-mediated caspase 9 activation (Kaufmann and Earnshaw, 2000) . In mammalian cells, signals upstream of caspase 9 activation involve mitochondria and can be inhibited by Bcl-2, leading to designation of these signals as the 'Bcl-2-inhibitable pathway,' the 'intrinsic pathway,' or the 'mitochondrial pathway' (Zimmermann et al., 2001) .
Both caspase activation and caspase activity are tightly controlled. As described below, caspase 9 activation is inhibited by antiapoptotic Bcl-2 family members and facilitated by proapoptotic Bcl-2 family members (Cory and Adams, 2002) . In addition, active caspases 3, 7, and 9 can be inhibited by XIAP, a member of the IAP family of proteins (Salvesen and Duckett, 2002) .
Bcl-2 family and control of the mitochondrial pathway
Mammalian cells express B20 different polypeptides that share some degree of similarity with Bcl-2, an antiapoptotic protein initially identified because its gene is translocated in indolent lymphomas (Adams and Cory, 1998; Gross et al., 1999; Cory and Adams, 2002) . These Bcl-2 family members can be divided into three groups. The first group, which includes Bcl-2, Bcl-x L and others, inhibits cell death. They contain four conserved regions termed BH ('Bcl-2 homology') domains that appear to be involved in various homotypic and heterotypic protein-protein interactions. The second group includes proapoptotic proteins such as Bax and Bak, which also contain multiple BH domains. Family members in the third group, which includes Bim, Bik, Bid, Bad, Hrk, Noxa, Puma, Bmf, and others, are also proapoptotic, but they only contain a BH3 domain and are often referred to as 'BH3-only polypeptides' (Adams and Cory, 1998; Huang and Strasser, 2000) .
Developmentally regulated cell death in C. elegans ( Figure 2 and Table 1 ) provides elegant examples of the roles of Bcl-2 family members in the control of cell death. Activation of CED-3, a caspase required for demise of all 131 somatic cells that ordinarily die during development, requires binding to the Apaf-1 homolog CED-4. This CED-3/CED-4 interaction is ordinarily prevented by the binding of the antiapoptotic Bcl-2 homolog CED-9 to CED-4. In cells fated to die, expression of the BH3-only family member EGL-1 leads to formation of EGL-1/CED-9 complexes, displacing CED-4 and allowing it to facilitate activation of CED-3 (Conradt and Horvitz, 1998; Chen et al., 2000) .
In mammalian cells, most of the short-term regulation of 'Bcl-2-inhibitable' apoptotic pathways is likewise achieved through activation of BH3-only proteins, although the activating events can be post-translational as well as transcriptional Puthalakath and Strasser, 2002) . Thus Bad is activated Figure 2 Comparison of initiator caspase activation across species. Conformational changes are indicated by changes in shape, and increased activity is indicated by a cross-hatched fill pattern. Adaptor/active caspase complexes have been shown to be multimers referred to as 'apoptosomes' in Drosophila and mammals. Question marks indicate current uncertainty as to whether DARK exists in an inactive conformation that requires activation by binding to cytochrome c or another mitochondrial component (Martin, 2002) by dephosphorylation, Bid by proteolytic cleavage, Bim by release from sequestration, and Noxa and Puma by transcription. According to current models, these polypeptides promote apoptosis by binding to antiapoptotic Bcl-2 family members (CED-9 homologs) or, in the case of cleaved Bid, to Bax and its homologs .
Even though human Bcl-2 can at least partially complement loss of its worm homolog Ced-9, demonstrating the high degree of conservation of these components (Hengartner et al., 1992; Vaux et al., 1992) , there are important differences between apoptotic pathways in worms and mammals. First, CED-4 appears to be capable of activating CED-3 without any accessory proteins (Irmler et al., 1997) . In contrast, full-length mammalian Apaf-1 requires interaction with cytochrome c, which is released from mitochondria during apoptosis, to induce a conformational change that facilitates the binding and activation of procaspase 9 (Boatright, 2003; Li et al., 1997) . Second, CED-9 binds directly to and inhibits CED-4 (Spector et al., 1997) . In mammalian cells, in contrast, neither Bcl-2 nor Bcl-x binds to Apaf-1 (Moriishi et al., 1999; Hausmann et al., 2000) . Instead, they inhibit Apaf-1 activation indirectly by preventing mitochondrial release of cytochrome c.
There are two current models for Bcl-2 function (Figure 3) . One suggests that Bcl-2, together with other family members, acts by directly preventing release of polypeptides from mitochondria . The second suggests that Bcl-2 acts on a yet to be identified CED-4 homolog to prevent activation of a caspase that can cleave substrates, including those on the mitochondria, causing release of cytochrome c (Adams and Cory, 2001; Marsden et al., 2002) . The first model requires mammalian Bcl-2 to have evolved activities different from those of its nematode homolog and implies that the role of caspases in apoptosis is vestigial, with loss of mitochondrial function and release of mitochondrial polypeptides such as apoptosis-inducing factor (AIF) (Daugas et al., 2000) being the important steps. While the second model is consistent with what we know about apoptosis in C. elegans and suggests that caspases are the key effectors of apoptosis, it requires the existence of an adaptor and a caspase for which there is currently little evidence.
IAP proteins and a second level of regulation
While Bcl-2 family members regulate the mitochondrial pathway prior to caspase activation, IAP proteins are thought to regulate apoptosis after caspase activation (Salvesen and Duckett, 2002) . Originally identified because of their ability to inhibit apoptosis in virusinfected insect cells (Crook et al., 1993) , this polypeptide family contains several species, including XIAP (X chromosome-linked mammalian inhibitor of apoptosis)/ MIHA (Mammalian IAP homolog A), cIAP1 (cellular IAP1)/MIHB, cIAP2/MIHC, ML-IAP (melanoma IAP)/Livin and neuronal apoptosis inhibitory protein (NAIP), some of which are capable of inhibiting active caspases 3, 7, and 9 in vitro (Deveraux and Reed, 1999; Salvesen and Duckett, 2002) . While low nanomolar concentrations of XIAP can inhibit caspases, cIAP1 and 2 are estimated to be 1000-fold less potent and might not exist in cells at high enough concentrations to directly inhibit caspases in vivo. In addition, the RING finger domains at the C termini of many of these antiapoptotic IAPs can transfer ubiquitin to associated polypeptides such as caspases, IAP antagonists and the IAP proteins themselves, thereby marking them for proteasomemediated degradation Yang et al., 2000; Suzuki et al., 2001) .
Some of the strongest evidence for regulation of apoptosis by IAP proteins has come from genetic studies in Drosophila (Hay, 2000; Martin, 2002) . As summarized in Figure 2 , the fly caspase-9 homolog DRONC is activated by the Apaf-1 homolog DARK/HAC-1/Dapa-1. The ability of DRONC to kill cells during development, however, is inhibited by the Drosophila IAP homolog DIAP1. On the other hand, this antiapoptotic activity of DIAP1 is antagonized by four genes, reaper (rpr), head involution defective (hid), grim and sickle, which control virtually all developmental cell death in Drosophila. Importantly, the polypeptides encoded by rpr, hid, grim, and sickle contain a short region of homology at their amino termini. Recent studies indicate that these amino-terminal polypeptides bind DIAP1, blocking its interaction with DRONC and facilitating DIAP1 degradation (Wu et al., 2001; Martin, 2002) . This interruption of DIAP1 function is required for normal developmental death in Drosophila. Data supporting similar roles for IAP proteins and their antagonists in the control of mammalian apoptosis are not as strong. While overexpression of XIAP can inhibit apoptosis (Duckett et al., 1996; Liston et al., 1996; Uren et al., 1996) , targeted XIAP disruption fails to yield a developmental phenotype in mice (Harlin et al., 2001) , either because of compensation by other IAP proteins or because the regulation of apoptosis by IAP proteins has become vestigial in mammals. Likewise, the importance of IAP antagonists in mammalian cells is less clear-cut. Even though mammalian cells contain Smac (second mitochondrial activator of caspases)/Diablo (direct IAP binding protein with low pI) and HtrA2/Omi, which are capable of binding to and antagonizing IAP proteins in the same way as Grim, HID, Reaper, and Sickle bind DIAP1 (Verhagen and Vaux, 2002) , there are again important differences. First, unlike the insect polypeptides, the mammalian IAP antagonists are sequestered in mitochondria and come in contact with XIAP only after Bcl-2-regulated release Verhagen et al., 2000; Adrian et al., 2001) . Second, unlike deletion of rpr, hid, or grim, deletion of Smac/Diablo did not result in a developmental phenotype or alter sensitivity to a range of apoptotic stimuli (Okada et al., 2002) , raising the possibility that the mammalian IAP antagonists might be much less important in the regulation of cell death, just like the mammalian IAP proteins.
Inhibition of cell death during oncogenesis
Why has such a complicated cell death process evolved in metazoans? It might have arisen initially as a defence against intracellular parasites, such as viruses; however, in larger animals it also acts to precisely counterbalance cell replication and maintain constant cell number in normal adult tissues. Any imbalance between cell production and cell destruction will, over time, dramatically alter the number of cells in a tissue, with potentially deleterious consequences.
Although several changes are required for development of the full-blown neoplastic phenotype (Hanahan and Weinberg, 2000) , one of the earliest changes required for a cancer to develop is an excess of cell production relative to cell death. In theory, this could be achieved by increasing cell division, decreasing apoptosis, or both. Histological examination of tumors is consistent with this theory. An increase in mitotic figures is a classical feature of most cancers. Apoptotic cells are also common in solid tumors (Wyllie, 1985) , possibly reflecting the deleterious effects of some of the proproliferative changes (see below). Nonetheless, as long as the death rate does not exceed the rate of cell division, the tumor will not regress.
The discovery of activated oncogenes in human cancers, and the formation of cancers in transgenic mice overexpressing oncogenes, has confirmed the importance of increased cell proliferation in oncogenesis (Hanahan and Weinberg, 2000; Evan and Vousden, 2001) . The finding that one of the genes translocated in follicular lymphomas, Bcl-2, encodes a cell death inhibitor suggested that inhibition of apoptosis could also lead to malignancy (Vaux et al., 1988) . Consistent with this possibility, Bcl-2 transgenic mice develop neoplasms, although it should be noted that tumors arise in Bcl-2 transgenic mice only with long latency (Strasser et al., 1993) .
As p53, which is the gene most commonly mutated in human cancers, promotes apoptosis via the 'Bcl-2-inhibitable' pathway, most likely by increasing transcription of the BH3-only proteins Puma and Noxa Puthalakath and Strasser, 2002) , there has been considerable interest in ascertain- Figure 3 Two models for apoptosis. Available and emerging data support two distinct models for control of apoptotic pathways. The model on the left invokes an essential role for mitochondria in most cases of apoptosis and suggests that, even if caspases are inhibited, cells will die from loss of mitochondrial functions and release of mitochondrial enzymes such as AIF, an oxidoreductase (Miramar et al., 2001) , and endonuclease G (Li et al., 2001b ). In the model on the right, caspases are required for all apoptotic cell death, and mitochondria play a nonessential role that serves to accelerate cell death. Although the model on the left has been widely accepted, recent evidence places activation of caspases, particularly caspase-2, upstream of mitochondrial dysfunction in some models of chemotherapy-induced apoptosis (Guo et al., 2002b; Lassus et al., 2002; Marsden et al., 2002; Paroni et al., 2002; Robertson et al., 2002) , raising the possibility that another adaptor, possibly regulated by Bcl-2 family members in a manner analogous to CED-4, regulates caspase activation upstream of mitochondria ing whether the antiapoptotic effects of p53 mutation contribute to carcinogenesis. Careful examination has demonstrated that p53 À/À mice commonly develop neoplasms, including T-cell lymphomas, at an early age, whereas Bcl-2 transgenic mice hardly ever do even though Bcl-2 transgenic thymocytes are at least as resistant to apoptosis as their p53 À/À counterparts (Strasser et al., 1994) . These observations suggest that the proapoptotic activity of p53 plays at best a minor role in tumor suppression in mice in vivo.
Is there evidence for inhibition of apoptotic pathways in clinical cancer? Recent studies have demonstrated changes that could affect either the death receptor pathway or the Bcl-2-inhibitable pathway in a wide variety of neoplasms (Table 2 ). Along the mitochondrial pathway, for example, Bcl-2 upregulation is observed in indolent lymphomas and a variety of additional neoplasms (Reed, 1999) , Bax mutations have been observed in mismatch repair-deficient colon and gastric cancers (Rampino et al., 1997; Ionov et al., 2000) , and loss of Apaf-1 expression (Soengas et al., 2001) as well as overexpression of the IAP ML-IAP/Livin (Vucic et al., 2000; Kasof and Gomes, 2001 ) has been observed in melanomas. Observations such as these have led to speculation that alterations in apoptotic pathways might be involved in the origin of human cancers and might contribute to resistance to chemotherapy. These conclusions, however, need to be treated cautiously for several reasons.
First, it is important to keep in mind that studies of clinical samples establish a correlation, not causality. It has been observed, for example, that Bax is often upregulated in breast cancer (Reed, 1997) . Given the postulated role of Bax as a proapoptotic protein, it is difficult to argue that Bax upregulation plays a role in the pathogenesis of this disorder. Instead, Bax appears to be upregulated through a poorly understood feedback loop that sometimes increases Bax levels when Bcl-2 rises Kaufmann et al., 1998) . In short, not every change in apoptotic components necessarily contributes to the pathogenesis of cancer.
Second, there is little evidence to date that alterations in apoptotic pathways similar to those observed in human cancers lead to spontaneous cancers when introduced into mice. To the contrary, only a few of these alterations have been shown to hasten the onset of malignancy even in cancer-prone mice. No increase in spontaneous tumors has been reported in mice lacking genes for Fas, FasL (Cohen and Eisenberg, 1991), Bax, Bak (Lindsten et al., 2000) , Bim (Bouillet et al., 1999) , Apaf-1 (Honarpour et al., 2000) , caspase 2 (Bergeron et al., 1998) or caspase 3 (Zheng and Flavell, 2000) , for example, or mice transgenic for XIAP (Conte et al., 2001) , the caspase 8 inhibitor CrmA (Smith et al., 1996) , or the broad-spectrum caspase inhibitor p35 (Izquierdo et al., 1999) . Thus, inhibition of cell death alone appears to be very weakly oncogenic. Although mice harboring Bcl-2 or Mcl-1 transgenes do develop lymphomas (Strasser et al., 1993; Zhou et al., 2001) , they do so with very long latency, with few arising before the mice are 12-18 months old. This long latency highlights the importance of secondary, cooperating mutations that must accompany the inhibition of apoptosis in order for tumors to develop. In contrast, stimulation of cell division by c-myc in transgenic mice generates lymphomas much more quickly, with half the mice succumbing at 10 weeks (Adams et al., 1985) . The fact that mice bearing both a myc and a bcl-2 transgene develop tumors when only days old indicates that the combination of increased proliferation and inhibition of cell death is very potent indeed (Strasser et al., 1993) . This last observation also implies that tumors arise more slowly in the myc-only mice than in the myc þ bcl-2 mice because potential transformed cells in the myconly mice are being removed by apoptosis. Although some have interpreted these results as suggesting that cmyc has intrinsic, direct, proapoptotic activity (the 'lock and key' model) in addition to its cell cycle effects (Juin et al., 1999) , another interpretation is that cells can detect cell cycle dysregulation caused by myc overexpression and respond by undergoing p53-mediated (Zindy et al., 1998) , Bcl-2-inhibitable (Eischen et al., 2001) apoptosis (the 'stimulus-response' model).
In summary, currently available information suggests that the process of carcinogenesis usually requires at least two cellular changes, one inhibiting apoptosis and another that facilitates cell proliferation (Green and Evan, 2002) . The fact that apoptotic cells can be found in cancers, even those with p53 mutations (Wachenfeld et al., 2001) , suggests that tumors in vivo may be close to equilibrium, with both high proapoptotic signals (e.g. due to disrupted cell cycle regulation from inappropriate myc expression) and high antiapoptotic activity (e.g. increased Bcl-2 expression). To the extent that this is the case, cancer cells might be just as easy to tip into apoptosis as normal cells despite the presence of alterations in their apoptotic pathways.
Chemotherapy and apoptosis
Consistent with the speculation that cancer cells remain susceptible to the induction of apoptosis, indolent lymphomas and chronic lymphocytic leukemia (CLL), which almost universally express high Bcl-2 levels (Hanada et al., 1993; Reed, 1995) , respond with dramatic and sometimes durable remissions after treatment with a variety of agents, including glucocorticoids, purine nucleoside analogues, and the anti-CD20 antibody rituximab (Rai et al., 2000; Keating et al., 2002; Kipps, 2002) . Although one might argue whether the effects of these agents reflect a direct toxic effect ('lock and key' model) or induction of apoptosis, recent studies have demonstrated caspase activation and other apoptotic changes in circulating CLL cells after rituximab treatment (Byrd et al., 2002) . Accordingly, these indolent B-cell neoplasms provide examples where apoptosis can be readily triggered by effective therapies despite high Bcl-2 expression.
What about other neoplasms and other treatments? After institution of therapy for acute leukemia, apoptosis can also be detected in circulating blasts (Li et al., 1994; Seiter et al., 1997; Stahnke et al., 2001) , providing evidence that apoptotic pathways are also activated in these disorders in vivo. In the solid tumor setting it is more difficult to demonstrate an increase in apoptosis because (i) the poor response of many solid tumors to existing agents limits the amount of apoptosis that might be expected and (ii) efficient phagocytosis of apoptotic cells makes it possible for extensive tumor regressions to occur with only modest increases in the number of apoptotic cells present at any point in time (Kyprianou et al., 1990) . Nonetheless, increased apoptosis has been demonstrated in murine solid tumors after effective antineoplastic treatment (Martin et al., 1994) .
Despite the current fascination with apoptotic pathways, it is important to stress that other processes might also contribute to cancer cell (and normal cell) demise (Houghton, 1999) . With the possible exception of glucocorticoids and the abl kinase inhibitor imatinib mesylate (STI571), practically all of the cancer therapies that have proven clinical utility have direct toxic effects on cellular metabolism. In addition, virtually all established and investigational antineoplastic agents can induce apoptosis in susceptible cell types in vitro (Kaufmann and Earnshaw, 2000) . These observations raise the question of how much of the killing by chemotherapy in vivo is due to direct toxicity vs induction of apoptosis. This question is extremely difficult to answer. Studies performed in vitro often look at short-term effects using drug concentrations that are different from those achievable in vivo. In addition, while studies have been performed in vitro using cells lacking one or two apoptotic pathway components, none of the studies has completely eliminated all apoptotic pathways (e.g. by knocking out FADD, Bak, and Bax in a single cell line). These studies are even less feasible in vivo because it is impossible to generate a mouse in which all of the apoptotic pathways are eliminated.
How does chemotherapy induce apoptosis?
Inhibition of any vital metabolic process can lead to stress responses, including apoptosis. For some therapies, the detection and signal transduction pathways have been elucidated. Damage to DNA caused by ionizing radiation or drugs, for example, can lead to stabilization of p53 (Giaccia and Kastan, 1998; Abraham, 2001 ) and consequent transcriptional activation of genes encoding a number of polypeptides, including Bax , Apaf-1 (Fortin et al., 2001; Kannan et al., 2001; Robles et al., 2001) , the BH3-only polypeptides Noxa and PUMA (Oda et al., 2000a; Yu et al., 2001) , and p53AIP1 (Oda et al., 2000b) . Each of these polypeptides can potentially activate the Bcl-2-inhibitable pathway. Because of the involvement of other transcriptional activators and repressors in expression of these polypeptides, not all of these polypeptides are regulated to the same extent by p53 in all model systems. The role of Bax transcription in p53-induced death, for example, has been questioned because it is difficult to demonstrate DNA damageinduced Bax upregulation in many cells, thymocytes from Bax À/À mice undergo p53-dependent apoptosis normally, and the putative p53 binding elements in the Bax promoter are not conserved between man and mouse (Knudson et al., 1995; Brady et al., 1996; Igata et al., 1999) . Likewise, the extent and importance of Noxa upregulation has been questioned (Yu et al., 2001) .
Because transfecting p53 À/À cells with bcl-2 causes a further reduction in apoptosis of irradiated cells (Strasser et al., 1994) , p53 cannot be the only mediator of DNA damage-induced apoptosis. For example, in mitogen-stimulated T cells, IRF-1 rather than p53 has been implicated as the mediator of radiation-induced apoptosis by the Bcl-2-inhibitable pathway (Tamura et al., 1995) .
In addition to DNA damage, apoptosis can be induced by inhibition of transcription, translation, DNA replication, or microtubule function. Apoptosis in response to these types of stresses is reduced in cells or transgenic mice overexpressing Bcl-2 (Sentman et al., 1991; Strasser et al., 1991) or cells containing targeted deletion of both Bax and Bak (Lindsten et al., 2000) . In contrast, apoptosis in response to these agents still occurs in cells or mice lacking Fas, FasL, or caspase 8 and in cells expressing the caspase 8 inhibitor CrmA, an inhibitor of FADD, or activated protein kinase C isoforms that inhibit the death receptor pathway (Eischen et al., 1997; Villunger et al., 1997; Varfolomeev et al., 1998; Yeh et al., 1998; Strasser, 2000, 2001; Meng et al., 2002) . Experiments such as these suggest that, with a few possible exceptions such as 5-fluorouracil (Tillman et al., 1999) , chemotherapy-induced apoptosis proceeds via the Bcl-2-inhibitable pathway. Nevertheless, increased expression of death receptors and their ligands has often been observed in cells treated with chemotherapeutic agents (Kaufmann and Earnshaw, 2000; Herr and Debatin, 2001 ). This upregulation of death receptor pathway components may reflect part of a generalized stress response, but there is little evidence that the death receptor pathway is required for the cells to undergo apoptosis in response to most chemotherapy.
How to study the role of apoptosis in drug resistance
If anticancer drugs kill cells by inducing apoptosis, and cancer cells have alterations that inhibit apoptotic pathways, then it stands to reason that these alterations might contribute to drug resistance. Although this hypothesis has been articulated by a number of authors (e.g. Green et al., 1994; Lowe, 1995; Hannun, 1997; Reed, 1999) , several concerns have stood in the way of its widespread acceptance.
First, there is frequent misunderstanding of this hypothesis. What is being postulated is resistance of cells relative to what their sensitivity would be if apoptotic pathways were not altered, not absolute resistance to therapy. Other changes in cancer cells, for example, their aberrant entry into the cell cycle and loss of checkpoints (Hartwell and Kastan, 1994; Sherr, 2000) , enhance sensitivity to anticancer drugs and undoubtedly contribute to the (admittedly limited) therapeutic index of these agents. What is being hypothesized is that the therapeutic index would be greater if neoplastic cells did not have antiapoptotic changes.
Second, there is considerable uncertainty regarding the best way to test the hypothesis that alterations in apoptotic pathways affect drug sensitivity. To take the example of the role of Bcl-2 in drug resistance, if an experiment merely measures apoptosis at a particular point in time, it will fail to address the concern that Bcl-2 might delay apoptosis without altering the ultimate fate of the cells (Yin and Schimke, 1995) . Colonyforming assays can measure longer term effects on cell survival but are subject to other limitations. Since clonogenic assays measure the ability of cells to proliferate, they do not distinguish between prolonged cell cycle arrest and cell death (Waldman et al., 1997) . Moreover, if a clonogenic assay is performed under conditions where only a small percentage of cells form colonies, it is possible that the results will reflect unique properties of the colony-forming cells rather than the fate of the bulk population (Schmitt and Lowe, 2001 ). An alternative approach is to measure the ability of a population to recover and proliferate at late time points after drug treatment in vitro or in vivo. This approach is considerably more labor intensive but has provided some of the most convincing evidence that Bcl-2 overexpression affects drug sensitivity (Schmitt and Lowe, 2001) .
Finally, the study of drug resistance in clinical material raises its own set of methodological issues. In any study of clinical samples, it is important that the percentage of neoplastic cells in the population be estimated and stated. Inclusion of samples that contain small percentages of neoplastic cells, for example, can potentially lead to erroneous conclusions if assays that measure a parameter in the entire population (e.g. RT-PCR or immunoblotting) are applied (Estrov et al., 1998) . For this reason, assays that measure parameters on a single-cell basis (e.g. flow cytometry or immunohistochemistry) might be preferable in some settings; however, it is important to realize the inherent difficulty of quantifying immunohistochemical assays and the potential for variation in results in different areas of a large tumor due to emergence of clones with varying properties. Once samples have been assayed, it is also important that results be analysed in statistically valid ways, including application of suitable corrections for the effects of multiple comparisons (Matthews and Farewell, 1988) . Finally, as mentioned above, it is important to keep in mind that analyses of clinical material can only establish correlations, not causality.
A role for altered apoptotic pathways in multidrug resistance?
When the preceding considerations are taken into account, is there any evidence that alterations in apoptotic pathways contribute to the drug resistance? We believe that a large and growing body of evidence supports the claim that alterations in certain Bcl-2 family members might contribute in some settings. This evidence is strongest for Bcl-2 itself.
Studies in clinical samples have demonstrated a correlation between high expression of Bcl-2 and poor prognosis in a number of neoplasms, including acute myelogenous leukemia, acute lymphocytic leukemia, non-Hodgkin's lymphomas, and postate cancer (Reed, 1995 (Reed, , 1999 . In further support of the hypothesis that Bcl-2 contributes to drug resistance, forced overexpression of Bcl-2 in tissue culture cells has been observed to prevent apoptosis due to several hundred different treatments, including the majority of agents used as cancer chemotherapy (Miyashita and Reed, 1992; Yang and Korsmeyer, 1996; Johnstone et al., 2002) . Determining whether the decreased number of apoptotic cells at any point in time translates into altered long-term cellular survival has been more problematic. Colonyforming assays have yielded conflicting results, with some studies showing that Bcl-2 enhances clonogenic survival (Miyashita and Reed, 1993) and others questioning this conclusion (Yin and Schimke, 1995; Lock and Stribinskiene, 1996; Kyprianou et al., 1997) . One potential factor complicating the use of colony-forming assays in this context has been the low efficiency of colony formation in some of the model systems (Schmitt and Lowe, 2001) . Assays that compare the ability of isogenic cells to regrow after drug treatment in vivo, however, have recently established that forced Bcl-2 overexpression can enhance the ability of lymphoma cells to recover after a variety of drug treatments (Schmitt and Lowe, 2001) .
Similar sorts of observations support the view that Bcl-x L might contribute to drug resistance. High Bcl-x L levels correlate with a poorer prognosis in patients with intermediate-grade lymphomas (Bairey et al., 1999) , squamous cell carcinoma of the oropharyx (Aebersold et al., 2001) , soft-tissue sarcomas (Kohler et al., 2002) , and myelodysplastic syndrome (Boudard et al., 2002) . Assays examining the ability of cells to regrow after drug treatment in vitro and in vivo have not only established the ability of Bcl-x L to enhance tumor cell repopulation after cytotoxic insults (Simonian et al., 1997; Liu et al., 1999) , but also suggested that Bcl-x L is a more potent inducer of cell survival under these conditions (Simonian et al., 1997) . The effects of other antiapoptotic Bcl-2 family members remain to be established in a similar fashion.
The effects of alterations in proapoptotic Bcl-2 family members also require further study. Although it has been reported that BAX deletion inhibits drug-induced apoptosis in HCT116 cells in vitro Theodorakis et al., 2002) , the effects of this alteration on drug sensitivity in vivo remain to be established. Moreover, it is important to emphasize that Bax À/À cells represent an extreme situation that might not occur in human cancers in vivo. Instead, mismatch repairdeficient tumors appear to have inactivating mutations in a single BAX allele (Rampino et al., 1997) , and it remains to be established whether the resulting cells or cell lines are deficient in Bax protein. If Bax is simply downregulated, then models in which Bax is downregulated might be more informative than those containing BAX deletions. Similar comments apply to Bak, which is currently thought to cooperate with Bax in facilitating the release of cytotoxic polypeptides from mitochondria after many cellular insults .
There is even less information available regarding alterations in BH3-only proteins. In perhaps the beststudied example, BIM deletion renders thymocytes selectively resistant to paclitaxel-induced apoptosis in vitro (Puthalakath et al., 1999) . It remains to be determined whether Bim À/À cells are resistant to paclitaxel in vivo and whether quantitative Bim alterations that fall short of complete deletion also affect drug sensitivity.
Since p53 induces cell death by engaging the Bcl-2-inhibitable apoptotic pathway, a discussion of this pathway would be incomplete without at least mentioning p53. p53 alterations appear to affect sensitivity to both ionizing radiation and drugs. Studies in tissue culture have indicated that p53 deletion can render both E1A/ras-transformed fibroblasts (Lowe et al., 1993) and HCT116 colon cancer cells (Bunz et al., 1999) resistant to the induction of apoptosis by various anticancer drugs in vitro. When the same cell lines are grown as xenografts, responses are diminished in the absence of p53. Consistent with these results, studies have also established that ionizing radiation or high-dose 5-fluorouracil induces less apoptosis in epithelial cells of the small and large intestines of p53 À/À mice compared to p53 þ / þ littermates (Merritt et al., 1997; Pritchard et al., 1998) . Collectively, these results suggest that p53 status can affect drug sensitivity. As indicated above, however, the relative importance of various p53 regulated proapopotic proteins remains to be determined. The entire issue of p53 and drug resistance is reviewed more comprehensively by El-Deiry (2003) in this issue.
Other alterations in apoptotic pathways might or might not affect drug sensitivity Current data supporting the role of alterations in other apoptotic regulators are not as strong. NAIP, XIAP, cIAP1, and cIAP2, were reported to diminish apoptosis triggered by a number of agents, including camptothecin and menadione in vitro (Liston et al., 1996) . Whether these effects result in enhanced long-term survival after drug treatment still remains to be established. A recent attempt to correlate expression of these polypeptides with drug sensitivity in the 60 cell lines used by the National Cancer Institute to screen potential anticancer drugs failed to demonstrate the postulated negative correlation (Tamm et al., 2000) . Unfortunately, 'drug sensitivity' in the latter study was measured only in 48 h assays, which might be too short to allow apoptotic changes to occur in many cell lines, and was quantified by calculating the drug concentration that inhibits proliferation by 50%, which reflects antiproliferative effects rather than cell killing. Accordingly, further studies, preferably using isogenic model systems, are required to determine whether enhanced expression of IAP proteins enhances the ability of tumor cell populations to survive drug treatment.
It is important to emphasize that not all BIRcontaining polypeptides (BIRPs) are necessarily caspase inhibitors (Silke and Vaux, 2001 ). Survivin, a human protein containing a single BIR, illustrates this point. Survivin was originally reported to be overexpressed in a variety of neoplasms (Ambrosini et al., 1997) . A growing number of studies have also indicated a correlation between elevated survivin levels and a poor prognosis, for example, in acute myelogenous leukemia, neuroblastoma and malignant glioma as well as cancers of the colon, prostate, ovary, breast, pancreas, and esophagus (reviewed in Mow et al., 2001; Kamihira et al., 2001; Chakravarti et al., 2002) . Several additional observations, however, have suggested that survivin might not be an inhibitor of apoptosis. First, the group that originally suggested an IAP function for survivin has been unable to demonstrate that it inhibits caspase 3 (Banks et al., 2000) . Second, survivin localizes to the mitotic apparatus, where it behaves like a typical chromosomal passenger protein . Third, targeted deletion of the mouse survivin gene is embryonic lethal but, unlike deletion of Bcl-x L , results in altered ability of cells to complete mitosis rather than an excess of apoptosis (Uren et al., 2000) . Given this information suggesting that survivin is a component of the mitotic machinery, how is one to intrepret the reports of poorer prognoses in patients with survivinexpressing neoplasms? Additional studies have demonstrated transcriptional activation of the survivin promoter under conditions where cells are actively cycling (Li and Altieri, 1999) . One possibility, therefore, is that survivin expression in a tumor reflects the number of cells that are actively cycling. If patients are treated with ineffective therapeutics (as is the case with many solid tumors), it is perhaps not surprising that patients with more proliferative neoplasms will have a poorer prognosis. According to this interpretation, the clinical association between poor prognosis and high survivin expression might not reflect any effect of survivin on apoptosis at all. Further studies are required to determine whether this interpretation is correct or whether survivin's role in mitosis affects tumor cell biology in some other way.
The effects of alterations in levels of Apaf-1 and caspases also require further study. Silencing of APAF-1 has been reported in melanoma cell lines and clinical samples (Soengas et al., 2001) . Consistent with prior observations in Apaf-1 À/À murine fibroblasts and thymocytes (Yoshida et al., 1998) , the Apaf-1-deficient melanoma cells exhibited diminished apoptosis in response to doxorubicin (Soengas et al., 2001) . Whether Apaf-1 deficiency also affects long-term viability after drug treatment remains to be determined. In contrast to alterations in antiapoptotic Bcl-2 family members or p53, which clearly alter long-term survival after drug treatment, it is possible that downregulation of Apaf-1, caspase-9, or the effector caspases will inhibit the rapid development of apoptotic changes without affecting long-term survival. Observations of Apaf-1, caspase 9, or caspase 3 knockout mice have shown that, with the exception of certain neurons, developmental cell death occurs normally in the absence of these components (Zheng et al., 1999; Honarpour et al., 2000) . It could be that release of proteins from mitochondria kills cells by a caspase-independent process, or that other caspases kill cells in the absence of Apaf-1 and caspase 9 (see Figure 3 ).
Do not throw out the baby
Despite the strength of recent evidence showing that alterations in Bcl-2, Bxl-x L , and p53 can affect drug sensitivity, it is important to emphasize two points. First, these conclusions are based on the examination in vivo of a total of four pairs of neoplastic cell lines, only two of which are carcinoma models. It is, therefore, unclear how widely applicable these conclusions are to other cellular contexts (Brown and Wouters, 1999) . Second, it is important to stress that these changes result in relative resistance to induction of apoptosis, not absolute resistance. As indicated above, cancer cells have a variety of defects in DNA repair and cell cycle checkpoint pathways that might counterbalance the effect of upregulated Bcl-2 or Bcl-x L by enhancing the sensitivity of cells to drug-induced apoptosis. Moreover, while Bcl-2 upregulation might prevent the rapid apoptotic death of cells, it is important to keep in mind that it would not prevent killing of cells by agents that have intrinsic toxicity, as long as the cells were treated with a sufficient dose for a sufficient time. A crucial issue is whether the apoptotic response of neoplastic cells to toxins occurs at a significantly lower dose of drug than is required for direct lethal effects. As a result of these outstanding issues, it is essential that improved but incomplete understanding of apoptotic pathways not be utilized prematurely to withhold or alter treatment. CLL provides an informative example. Based on the fact that high levels of Bcl-2 are observed in the vast majority of CLL cases (Hanada et al., 1993) , one might predict that CLL would be highly resistant to chemotherapy. Taken to its extreme, such a prediction would suggest that it is fruitless to treat CLL with currently available agents. Nothing could be further from the truth. CLL cells also appear to contain additional alterations, for example, mutations in the DNA damage-responsive kinase ATM (Bullrich et al., 1999; Pettitt et al., 2001) , that increase their sensitivity to various agents. As a consequence, CLL remains sensitive to the induction of apoptosis by a variety of agents in vitro (Thomas et al., 1996; Chandra et al., 1998) and in vivo (Byrd et al., 2002) .
Put another way, a diverse and useful group of chemotherapeutic drugs has been identified over the past 50 years by empirical means. In retrospect it is clear that most if not all can induce apoptosis in susceptible cells (Kaufmann and Earnshaw, 2000) . Some, such as dexamethasone, probably work only by inducing apoptosis. This new understanding has sometimes obscured the fact that most of these drugs can kill cells independent of the apoptotic response (Figure 1 ). Whether they work by inducing apoptosis or not, there is abundant evidence that these drugs can have clinically useful effects even in cells overexpressing Bcl-2 or with mutant p53.
In the late 1990s there was similar debate about whether p53 mutations were responsible for resistance to radiotherapy (Finkel, 1999) . The demonstration that p53 was required for rapid interphase death of particular cells was extrapolated by some to indicate that treating patients with p53-mutant tumors was hopeless. Luckily, radiation oncologists who had extensive experience successfully treating patients with p53 mutant tumors ingored this advice.
Enhancing the apoptotic response
As illustrated in the preceding sections, the complexity of human cancers can make it difficult to extract clinically pertinent conclusions from controlled experiments in the lab. Nonetheless, it is important not to completely ignore the biochemical findings. If alterations in apoptotic pathways render cancer cells more resistant than they would be in the absence of those alterations, then enhanced understanding of apoptotic pathways might suggest ways of sensitizing cancers to existing therapies or even entirely new approaches for the treatment of cancer. Although space limitations preclude a comprehensive discussion of novel therapeutic approaches that are being tested, a number of examples are described in the following sections.
Imatinib mesylate (STI571) as a paradigm
Imatinib mesylate provides an excellent example of an agent that might act, at least in part, by altering apoptotic pathways. Studies dating to the early 1990s demonstrated that transfection with p190
Bcr/abl or p210
Bcr/ abl diminished the apoptotic response of cell lines to agents that activate the Bcl-2-inhibitable pathway (Laneuville et al., 1994; McGahon et al., 1994; Cortez et al., 1995) . Subsequent analysis has demonstrated that this reflects Bcr/abl-mediated phosphorylation of STAT5 (signal transducer and activator of transcription-5), which upregulates BCL-X transcription (Shuai et al., 1996; Amarante-Mendes et al., 1998; Horita et al., 2000) , as well as Bcr/abl-mediated activation of the phosphatidylinositol-3 (PI-3) kinase/Akt pathway (Skorski et al., 1995; Neshat et al., 2000) , which can potentially inhibit the mitochondrial pathway in a number of ways (Kaufmann and Gores, 2000; Vivanco and Sawyers, 2002) . Treatment with the somewhat selective Bcr/abl kinase inhibitor imatinib mesylate (Druker et al., 1996) results in downregulation of Bclx L and inhibition of the PI-3 kinase/Akt pathway in Bcr/ abl-positive cells (Horita et al., 2000; Neshat et al., 2000) . These changes sensitize Bcr/abl-positive cells to the cytotoxic effects of other agents in vitro (reviewed in La Rosee et al., 2002) . More surprising, however, has been the demonstration that imatinib by itself induces complete hematological and cytogenetic responses in a substantial fraction of patients with chronic-phase chronic myelogenous leukemia (Druker et al., 2001; Kantarjian et al., 2002) . Studies in tissue culture have demonstrated that imatinib can induce apoptosis through activation of the mitochondrial pathway in Bcr/abl-positive cell lines (Dan et al., 1998; Fang et al., 2000; Mow et al., 2002) . Whether the effects of imatinib on apoptotic pathways play a role in its clinical effects, however, remains somewhat controversial. A recent study of the effects of imatinib on CML marrow progenitors suggests that the predominant effect of clinically achievable drug doses is inhibition of Bcr/ablinduced proliferation (Holtz et al., 2002) . Importantly, however, cells from patients with the best clinical response to imatinib also exhibited apoptotic changes in response to low drug concentrations in vitro, a point that was ignored in the discussion of Holtz et al. Further studies are required to define not only the extent to which imatinib-induced apoptosis plays a role in the successful treatment of CML, but also to determine whether imatinib-induced downregulation of Bcl-x L and the PI-3/Akt pathway will translate into improved therapy for Bcr/abl-driven acute leukemias.
Altering effective levels of Bcl-2
In view of the widespread expression of Bcl-2 in human cancers (Reed, 1999) , there has been considerable interest in downregulating or inhibiting this polypeptide. In theory, this approach could be used to treat follicular lymphoma as well as increase the propensity of other cells to undergo apoptosis in response to chemotherapy. A series of studies (reviewed in Cotter, 1999) has demonstrated that a phosphorothioate oligonucleotide complementary to the first 18 nucleotides of the Bcl-2 coding sequence (now called G3139, augmerosen, or Genasense) is particularly effective at downregulating Bcl-2 in lymphoma cells containing the t(14;18) chromosomal translocation and inhibiting engraftment of these cells in nude mice. Based on these results, a phase I study of G3139 administered as a 14-day continuous infusion was completed in 21 patients with relapsed nonHodgkin's lymphoma (Cotter, 1999; Waters et al., 2000) . G3139 caused downregulation of Bcl-2 protein in 58% of cases and responses in 14% of patients, with one complete response lasting X36 months. Ongoing trials are examining G3139 as a single agent in melanoma, prostate, breast, and colon cancer (Banerjee, 2001) .
On the other hand, current understanding of Bcl-2 as a regulator of the mitochondrial pathway (see above) suggests that Bcl-2 downregulation might be more effective when combined with other proapoptotic stimuli. Several studies have shown, for example, that cytarabine-induced apoptosis can be enhanced in vitro by treating leukemia cells with Bcl-2 antisense oligonucleotides (Reed et al., 1990; Campos et al., 1994) . Based on this rationale, recently reported pilot studies have evaluated G3139 in combination with dacarbazine, paclitaxel, docetaxel, or mitoxantrone (Chi et al., 2001; Tolcher, 2001; Jansen et al., 2000; Rudin et al., 2002) . One concern with these types of combinations would be that Bcl-2 downregulation might sensitize normal tissues to the chemotherapy, thereby enhancing toxicity. Enhanced toxicity has not been a major problem in the combination trials even though G3139 doses were sufficient to downregulate Bcl-2 levels in accessible surrogate tissues (Jansen et al., 2000; Chi et al., 2001; Rudin et al., 2002) . Phase III trials are required to determine whether this approach enhances the efficacy of the conventional agents.
BH3 mimetics
Antiapoptotic Bcl-2 family members are antagonized by BH3-only proteins in vitro and in vivo. This antagonism depends on the interaction between the BH3 domain, a region containing 9 amino acids, on the BH3-only protein and a cleft in antiapoptotic Bcl-2 family members . This raises the possibility that small-molecule BH3-only protein mimetics could be identified and used to antagonize Bcl-2 or Bcl-x L function. A number of such compounds have been reported Degterev et al., 2001; Tzung et al., 2001) . Whether these can be turned into useful drugs for indolent B-cell lymphomas or agents that modulate the action of other anticancer treatments remains to be seen.
Modulation of antiapoptotic IAP protein function
As indicated above, data linking elevated XIAP, cIAP1, or cIAP2 to drug resistance in the clinical setting are currently relatively limited. Based on studies showing that elevated XIAP expression can inhibit apoptosis in cell lines in vitro, several groups have investigated the effects of XIAP antisense approaches in model systems. Antisense molecules that reduce XIAP levels sensitize non-small cell lung cancer cells to radiation (Holcik et al., 2000) and ovarian cancer cells to cisplatin-induced apoptosis (Li et al., 2001a) . Whether this approach can selectively sensitize cancer cells to proapoptotic stimuli in vivo remains to be demonstrated.
Alternatively, small molecules that mimic the Ntermini of the IAP antagonists Smac/Diablo or HtrA2/ Omi might be useful to counter IAP activity in vivo. Recent studies have shown that the N-terminal 6-8 amino acids of Smac, when coupled to a sequence that carries them through the plasma membrane, can enhance apoptosis in tissue culture cells treated with a wide variety of agents (Arnt et al., 2002; Fulda et al., 2002; Guo et al., 2002; Yang et al., 2003) . Importantly, the same approach enhances the antineoplastic effects of TRAIL in a brain tumor model in vivo (Fulda et al., 2002) . Future studies will undoubtedly determine whether the effects of cytotoxic chemotherapeutic agents are also enhanced in vivo and whether the N-terminal Smac sequence can be turned into an efficacious smallmolecule peptidomimetic.
Death receptor ligands
The possibility of killing cancer cells by ligating death receptors has been investigated for a long time. Although TNF-a, the founding member of the DR ligand family, kills a number of cancer and leukemia cell lines, the septic shock-like syndrome caused by this agent limits its ability to be administered systemically (Lejeune et al., 1998) . Accordingly, TNF-a is reserved for local infusions into isolated, perfused limbs. Interestingly, recent analysis has demonstrated that TNF-ainduced antitumor effects require TNF receptors on tumor endothelial cells, not on the cancer cells themselves (Stoelcker et al., 2000) . These results, which suggest that TNF-a kills cancer cells indirectly by causing constriction of their blood supply, provide a nice explanation for the observation that TNF causes necrosis in vivo rather than apoptosis.
Several observations raise the possibility that the more recently identified TNF family member TNF-arelated apoptosis inducing ligand (TRAIL) might be more suitable for systemic treatment of cancer and leukemia (Ashkenazi, 2002) . First, TRAIL is utilized by interferon-g-stimulated lymphocytes and natural killer cells to kill their targets, which include transformed cells (Walczak and Krammer, 2000) . Second, the limited expression of DR4 and DR5 in normal adult cells (Schulze-Osthoff et al., 1998) raises the possibility that the TRAIL might exhibit some selectivity for solid tumors and leukemia. Consistent with this view, recombinant TRAIL kills neoplastic cell lines in vitro and shrinks tumors in animals (Ashkenazi et al., 1999; Walczak et al., 1999) . Alternatively, it has also been reported that certain antibodies to TRAIL receptors can activate receptor-mediated signaling and kill target cells (Ichikawa et al., 2001) . Clinical trials of these agents are awaited with interest.
In short, recent advances in understanding apoptotic pathways and their regulation have led to the testing of a number of approaches designed to alter the apoptotic sensitivity of cells or directly induce apoptosis. Ongoing preclinical and clinical studies should provide important information about the efficacy of these approaches over the next several years.
Inhibiting apoptosis to treat cancer
An alternative approach would be to inhibit therapyinduced apoptosis in normal tissues. The radiation or chemotherapy dose that can be administered is usually limited by toxic side effects, such as damage to the gastrointestinal system and bone marrow. Curative doses often cannot be given because of lethal side effects, many of which appear to result from the apoptosis of normal cells. In view of the role of wildtype p53 in these toxic effects, it has been proposed that p53 inhibitors might protect normal cells, whereas cancer cells lacking functional p53 would not be protected (Komarov et al., 1999) . Preliminary analysis has demonstrated that one p53 inhibitor, pifithrin-alpha, inhibits the toxic effects of lethal g-irradiation (Komarov et al., 1999) . Studies demonstrating that this approach will improve the therapeutic index in p53-deficient tumors are awaited with interest. The possibility that other antiapoptotic drugs, such as caspase inhibitors, might also reduce the side effects of chemotherapy, or allow higher doses to be tolerated, might also merit further investigation.
Summary
Recent studies have provided increased understanding of the manner in which apoptotic pathways are regulated. At the same time, various alterations in these apoptotic pathways have been identified in cancer cell lines and clinical tumor specimens. The idea that these alterations simultaneously contribute to the processes of carcinogenesis and drug resistance is an appealing one. Additional rigorous experiments in suitable model systems are required to determine whether qualitative and quantitative changes in apoptotic pathways actually do contribute to drug resistance in a clinically meaningful sense, that is, in the ability of cells to withstand drug treatment and subsequently repopulate their environment. Insightful, statistically rigorous analyses of clinical material are required to identify qualitative and quantitative alterations in apoptotic pathways in various tumor types. Moreover, carefully controlled preclinical and clinical studies are needed to determine whether interventions that alter the apoptotic threshold truly enhance the efficacy of anticancer therapies. Until these types of studies are performed, the idea that altered apoptotic pathways contribute to clinical drug resistance must be considered an attractive hypothesis rather than an established fact.
